OncoMatch/Clinical Trials/NCT05687136
Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and Tuvusertib (M1774) for Advanced Solid Tumors
Is NCT05687136 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1 trial studies multiple treatments including Peposertib and Tuvusertib for advanced malignant solid neoplasm.
Treatment: Peposertib · Tuvusertib — This phase I trial tests the safety, side effects and best dose of peposertib (M3814) in combination with tuvusertib (M1774) in treating patients with solid tumors that have spread to other places in the body (advanced). Peposertib and tuvusertib stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Tumor Agnostic
Biomarker criteria
Required: ATM inactivating mutation
inactivating ATM mutations
Required: MYC amplification
MYC amplification
Required: FBXW7 mutation
mutation of FBXW7
Required: CCNE1 amplification
CCNE1 amplification
Required: ARID1A mutation
SWI/SNF member mutation (ARID1A, PBRM1, SMARCA4, ARID2, ARID1b, SMARCB1, SMARCA2, SS18)
Required: PBRM1 mutation
SWI/SNF member mutation (ARID1A, PBRM1, SMARCA4, ARID2, ARID1b, SMARCB1, SMARCA2, SS18)
Required: SMARCA4 mutation
SWI/SNF member mutation (ARID1A, PBRM1, SMARCA4, ARID2, ARID1b, SMARCB1, SMARCA2, SS18)
Required: ARID2 mutation
SWI/SNF member mutation (ARID1A, PBRM1, SMARCA4, ARID2, ARID1b, SMARCB1, SMARCA2, SS18)
Required: ARID1B mutation
SWI/SNF member mutation (ARID1A, PBRM1, SMARCA4, ARID2, ARID1b, SMARCB1, SMARCA2, SS18)
Required: SMARCB1 mutation
SWI/SNF member mutation (ARID1A, PBRM1, SMARCA4, ARID2, ARID1b, SMARCB1, SMARCA2, SS18)
Required: SMARCA2 mutation
SWI/SNF member mutation (ARID1A, PBRM1, SMARCA4, ARID2, ARID1b, SMARCB1, SMARCA2, SS18)
Required: SS18 mutation
SWI/SNF member mutation (ARID1A, PBRM1, SMARCA4, ARID2, ARID1b, SMARCB1, SMARCA2, SS18)
Required: ATRX mutation
mutation or loss of expression of ATRX/DAXX
Required: ATRX loss
mutation or loss of expression of ATRX/DAXX
Required: DAXX mutation
mutation or loss of expression of ATRX/DAXX
Required: DAXX loss
mutation or loss of expression of ATRX/DAXX
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: standard therapy
Progression on at least one prior standard therapy (if no standard therapy exists, the patient may be allowed if the treating investigator deems appropriate).
Lab requirements
Blood counts
Hemoglobin >= 9 g/dL; Absolute neutrophil count >= 1,500/mcL; Platelets >= 100,000/mcL
Kidney function
Glomerular filtration rate (GFR) >= 60 mL/min/1.73m^2
Liver function
Total bilirubin <= 1.5 x institutional ULN; AST/ALT <= 3x ULN or <= 5x ULN if liver metastases are present
Cardiac function
QTcF (using the Fridericia correction calculation) of < 470 msec; NYHA class 2B or better
Hemoglobin >= 9 g/dL. Absolute neutrophil count >= 1,500/mcL. Platelets >= 100,000/mcL. Total bilirubin <= 1.5 x institutional ULN. AST/ALT <= 3x ULN or <= 5x ULN if liver metastases are present. Glomerular filtration rate (GFR) >= 60 mL/min/1.73m^2. QTcF (using the Fridericia correction calculation) of >= 470 msec. NYHA class 2B or better.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- National Cancer Institute Developmental Therapeutics Clinic · Bethesda, Maryland
- National Institutes of Health Clinical Center · Bethesda, Maryland
- Massachusetts General Hospital Cancer Center · Boston, Massachusetts
- Dana-Farber Cancer Institute · Boston, Massachusetts
- NYU Langone Hospital - Long Island · Mineola, New York
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05687136 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received standard therapy.
Does this trial require ATM?
Yes, ATM inactivating mutation is a required biomarker for enrollment.
Does this trial require MYC?
Yes, MYC amplification is a required biomarker for enrollment.
Does this trial require FBXW7?
Yes, FBXW7 mutation is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify